The brain acts as the body’s central command, overseeing diverse functions including thought, memory, speech, movement, and the regulation of various organs. When healthy, the brain functions seamlessly and automatically; however, disruptions can lead to serious conditions such as Alzheimer’s Disease, Brain Cancer, Stroke, and Epilepsy. Epilepsy, a neurological disorder marked by recurrent seizures, results from irregular electrical activity in the brain. These seizures, which can strain both patients and neurologists, are characterized by symptoms like the loss of awareness, unusual behavior, and confusion. This study presents an efficient EEG-based epileptic seizure detection framework utilizing a hybrid Convolutional Neural Network (CNN), Long Short-Term Memory (LSTM), and Gated Recurrent Unit (GRU) models approach to support automated and accurate diagnosis. Handling imbalanced EEG data, which can otherwise bias model outcomes and reduce predictive accuracy, is a key focus. Experimental results indicate that the proposed framework generally outperforms other Deep Learning and Machine Learning techniques with the highest accuracy at 99.13%. Likewise, an Explainable Artificial Intelligence (XAI) called SHAP (SHapley Additive exPlanations) is utilized to analyze the results and to improve the interpretability of the models from medical decision-making. This framework aligns with the objectives of the Medical Internet of Things (MIoT), advancing smart medical applications and services for effective epileptic seizure detection.

Background: Breast cancer is one of the major causes of mortality globally. Therefore, different Machine Learning (ML) techniques were deployed for computing survival and diagnosis. Survival analysis methods are used to compute survival probability and the most important factors affecting that probability. Most survival analysis methods are used to deal with clinical features (up to hundreds), hence applying survival analysis methods like cox regression on RNAseq microarray data with many features (up to thousands) is considered a major challenge.Methods: In this paper, a novel approach applying autoencoder to reduce the number of features is proposed. Our approach works on features reconstruction, and removal of noise within the data and features with zero variance across the samples, which facilitates extraction of features with the highest variances (across the samples) that most influence the survival probabilities. Then, it estimates the survival probability for each patient by applying random survival forests and cox regression. Applying the autoencoder on thousands of features takes a long time, thus our model is applied to the Graphical Processing Unit (GPU) in order to speed up the process. Finally, the model is evaluated and compared with the existing models on three different datasets in terms of run time, concordance index, and calibration curve, and the most related genes to survival are discovered. Finally, the biological pathways and GO molecular functions are analyzed for these significant genes.Results: We fine-tuned our autoencoder model on RNA-seq data of three datasets to train the weights in our survival prediction model, then using different samples in each dataset for testing the model. The results show that the proposed AutoCox and AutoRandom algorithms based on our feature selection autoencoder approach have better concordance index results comparing the most recent deep learning approaches when applied to each dataset. Each gene resulting from our autoencoder model weight is computed. The weights show the degree of effect for each gene upon the survival probability. For instance, four of the most survival-related experimentally validated genes are on the top of our discovered genes weights list, including PTPRG, MYST1, BG683264, and AK094562 for the breast cancer gene expression dataset. Our approach improves the survival analysis in terms of speeding up the process, enhancing the prediction accuracy, and reducing the error rate in the estimated survival probability.

Communication between sensors spread everywhere in healthcare systems may cause some missing in the transferred features. Repairing the data problems of sensing devices by artificial intelligence technologies have facilitated the Medical Internet of Things (MIoT) and its emerging applications in Healthcare. MIoT has great potential to affect the patient's life. Data collected from smart wearable devices size dramatically increases with data collected from millions of patients who are suffering from diseases such as diabetes. However, sensors or human errors lead to missing some values of the data. The major challenge of this problem is how to predict this value to maintain the data analysis model performance within a good range. In this paper, a complete healthcare system for diabetics has been used, as well as two new algorithms are developed to handle the crucial problem of missed data from MIoT wearable sensors. The proposed work is based on the integration of Random Forest, mean, class' mean, interquartile range (IQR), and Deep Learning to produce a clean and complete dataset. Which can enhance any machine learning model performance. Moreover, the outliers repair technique is proposed based on dataset class detection, then repair it by Deep Learning (DL). The final model accuracy with the two steps of imputation and outliers repair is 97.41% and 99.71% Area Under Curve (AUC). The used healthcare system is a web-based diabetes classification application using flask to be used in hospitals and healthcare centers for the patient diagnosed with an effective fashion.

Background: Recently, drug repositioning has received considerable attention for its advantage to pharmaceutical industries in drug development. Artificial intelligence techniques have greatly enhanced drug reproduction by discovering therapeutic drug profiles, side effects, and new target proteins. However, as the number of drugs increases, their targets and enormous interactions produce imbalanced data that might not be preferable as an input to a prediction model immediately.Methods: This paper proposes a novel scheme for predicting drug–target interactions (DTIs) based on drug chemical structures and protein sequences. The drug Morgan fingerprint, drug constitutional descriptors, protein amino acid composition, and protein dipeptide composition were employed to extract the drugs and protein’s characteristics. Then, the proposed approach for extracting negative samples using a support vector machine one-class classifier was developed to tackle the imbalanced data problem feature sets from the drug–target dataset. Negative and positive samplings were constructed and fed into different prediction algorithms to identify DTIs. A 10-fold CV validation test procedure was applied to assess the predictability of the proposed method, in addition to the study of the effectiveness of the chemical and physical features in the evaluation and discovery of the drug–target interactions.Results: Our experimental model outperformed existing techniques concerning the curve for receiver operating characteristic (AUC), accuracy, precision, recall F-score, mean square error, and MCC. The results obtained by the AdaBoost classifier enhanced prediction accuracy by 2.74%, precision by 1.98%, AUC by 1.14%, F-score by 3.53%, and MCC by 4.54% over existing methods.